MetaCap

CRISPR Therapeutics (CRSP) vs Vericel (VCEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vericel (VCEL) has outperformed CRISPR Therapeutics (CRSP) over the past year, gaining 45.3% versus a loss of 22.2%. Over five years, VCEL leads with a +50.1% price change compared with -50.4% for CRSP. CRISPR Therapeutics is the larger company by market cap ($3.79 billion vs $2.94 billion), about 1.3 times the size, while Vericel is growing revenue faster (+16.5% vs -90.6%).

Vericel converts more of its revenue into profit, with a net margin of 6.0% versus -16569.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRSP-22.16%VCEL+45.33%
+54%+12%-30%
Nov 21, 20251 yearNov 20, 2026
CRSP-52.57%VCEL+29.75%
+39%-13%-65%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRSP versus VCEL key metrics
MetricCRSPVCEL
Share price$39.10$57.52
Market cap$3.79B$2.94B
1-day change+0.44%-1.27%
YTD return-25.44%+59.73%
1-year return-22.16%+45.33%
5-year return-50.37%+50.14%
P/E ratio (TTM)—89.88
Forward P/E—61.06
EPS (TTM)$-4.73$0.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.51M$276.26M
Revenue growth (YoY)-90.59%+16.45%
Net income (latest FY)$-581.60M$16.52M
Gross margin—74.42%
Operating margin-18933.65%4.00%
Net margin-16569.77%5.98%
52-week high$63.45$59.75
52-week low$38.15$28.95
Distance from 52-week high-38.38%-3.73%
Analyst consensusbuystrong_buy
Avg. price target upside+118.47%+13.75%
Average volume1.74M664.34K
Shares outstanding97.00M51.03M
Employees—398
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VCEL has outperformed CRSP by 67.5 percentage points over the past year.
  • Vericel is more profitable, keeping 6.0 cents of every revenue dollar as net income versus -16569.8 cents for CRISPR Therapeutics.
  • Vericel grew revenue faster in its latest fiscal year (+16.45% vs -90.59%).

About CRISPR Therapeutics

CRSP stock →

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

About Vericel

VCEL stock →

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 398 employees

CRSP vs VCEL FAQ

Which is bigger, CRISPR Therapeutics or Vericel?

CRISPR Therapeutics (CRSP) is larger, with a market capitalization of $3.79B compared with $2.94B for Vericel (VCEL).

Which stock has performed better over the past year, CRSP or VCEL?

VCEL returned +45.33% over the past 12 months, compared with -22.16% for CRSP (price return, excluding dividends). Past performance does not predict future results.

Are CRISPR Therapeutics and Vericel in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons